"Oesophageal adenocarcinoma" trang 1 - tải miễn phí từ tailieunhanh
Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: A randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma

Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: A randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma
11    17    1
Visceral adipose tissue modulates radiosensitivity in oesophageal adenocarcinoma

Visceral adipose tissue modulates radiosensitivity in oesophageal adenocarcinoma
10    83    0
Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma

Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma
7    48    1
Silencing microRNA-330-5p increases MMP1 expression and promotes an invasive phenotype in oesophageal adenocarcinoma

Silencing microRNA-330-5p increases MMP1 expression and promotes an invasive phenotype in oesophageal adenocarcinoma
11    41    0
NEOSCOPE: A randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma

NEOSCOPE: A randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma
9    69    1
Apoptosis and autophagy markers predict survival in neoadjuvant treated oesophageal adenocarcinoma patients

Apoptosis and autophagy markers predict survival in neoadjuvant treated oesophageal adenocarcinoma patients
12    1    1
A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients

A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients
8    66    1
Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: A retrospective study

Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: A retrospective study
10    54    1
EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus

EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus
14    65    1